Bone-aware monitoring and adaptive nutrition system for adults on GLP-1 therapy

Overview

Gaston AI is developing a bone-aware monitoring and nutrition system for adults on GLP-1 therapy. The solution combines clinical risk factors, dietary intake, physical function tests, vitamin D status, and bone turnover markers to identify individuals at elevated risk of bone loss during rapid weight loss. It then uses the NutriIQ nutrition engine to generate personalized, compact, nutrient-dense meal recommendations—suited to smaller appetites—that close protein, calcium, and vitamin D gaps.

This offering matters because GLP-1-mediated weight loss can cost bone as well as fat, and many users do not meet reference intakes for vitamin D or calcium. Bone turnover markers such as CTX and P1NP can shift within months, well before DXA scans detect bone mineral density changes. The system is designed to complement medical care, not replace it: prescribing clinicians keep full control of medication, while the platform adds a proactive bone-health layer to weight-management programs, clinical nutrition services, and digital health applications.

Technical specifications

The system integrates multiple data sources to create a personalized bone-health picture:

• Fracture-risk factors, weight-loss rate, dietary intake, physical function (grip and chair-stand tests), vitamin D status, and the bone turnover markers CTX and P1NP are combined into risk rules.
• A Bone Resilience Score updates weekly from diet, activity, and function data, and adapts the nutrition plan as the score changes.
• Biomarkers are re-tested every six weeks, enabling earlier course correction than imaging-based approaches.
• NutriIQ, Gaston AI's nutrition engine, maps foods into nutrient-dense, compact meal options targeted at protein, calcium, and vitamin D needs.
• The solution builds on Gaston AI's existing risk modeling and nutrition engine, and is designed for integration into clinical or consumer-facing digital platforms.

Key limitations include biological variability in turnover markers and user adherence to monitoring and nutrition plans; the planned validation directly tests both.

Technology readiness level

The bone module is at an early development stage. The next milestone is a 12-week proof-of-concept study in adults in their first eight weeks of GLP-1 therapy. The study will measure CTX, P1NP, 25(OH)D, diet records, grip strength, chair-stand performance, and body composition at defined intervals, with weekly rescoring and adaptive nutrition. Success will be judged on data completeness, achievement of protein, calcium, and vitamin D targets, direction of bone turnover marker change, lean mass and function, and product acceptability. Results will inform a go/no-go decision for a longer controlled study with DXA.